HUP0104917A2 - Azepinoindolszármazékok, előállításuk és alkalmazásuk - Google Patents

Azepinoindolszármazékok, előállításuk és alkalmazásuk

Info

Publication number
HUP0104917A2
HUP0104917A2 HU0104917A HUP0104917A HUP0104917A2 HU P0104917 A2 HUP0104917 A2 HU P0104917A2 HU 0104917 A HU0104917 A HU 0104917A HU P0104917 A HUP0104917 A HU P0104917A HU P0104917 A2 HUP0104917 A2 HU P0104917A2
Authority
HU
Hungary
Prior art keywords
atom
group
alkyl
hydrogen
carbon
Prior art date
Application number
HU0104917A
Other languages
English (en)
Inventor
Roland Grandel
Thomas Höger
Michael Kock
Wilfried Lubisch
Reinhold Müller
Sabine Schult
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0104917A2 publication Critical patent/HUP0104917A2/hu
Publication of HUP0104917A3 publication Critical patent/HUP0104917A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A tal lm ny t rgy t ltal nos képletű - ahol A adott esetben szubsztitult szénl nc, X1 kénatom, oxigénatom vagy -NH-csoport; X2 szénatom,amely adott esetben egy szénl ncot hordoz, vagy nitrogénatom; X3nitrogénatom vagy egy -C-R2 ltal nos képletű csoport, amelyben R2hidrogénatom, alkil-, alkil-fenil- vagy fenilcsoport; R1 hidrogén-,halogénatom, alkil-, hidroxi-, nitro-, trifluor-metil-, ciano-, -NR11R12, -NH-CO-R13 ltal nos képletű vagy alkoxicsoport, amelyekbenR11 és R12 hidrogénatom vagy alkilcsoport, R13 hidrogénatom, alkil-,alkil-fenil- vagy fenilcsoport; és B egy mono-, bi- vagy triciklikusgyűrű, amely adott esetben szubsztitu lt és heteroatomokat istartalmaz új azepinoindol-sz rmazékok, elő llít suk és poli(ADP-ribóz)-polimer z enzim inhibitoraiként gyógyszerkészítmények elő llíts ra való alkalmaz suk képezik. Ó
HU0104917A 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof HUP0104917A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
PCT/EP2000/009024 WO2001023390A2 (de) 1999-09-28 2000-09-15 Azepinoindol-derivate, deren herstellung und anwendung

Publications (2)

Publication Number Publication Date
HUP0104917A2 true HUP0104917A2 (hu) 2002-04-29
HUP0104917A3 HUP0104917A3 (en) 2002-12-28

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104917A HUP0104917A3 (en) 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof

Country Status (17)

Country Link
EP (1) EP1183259A2 (hu)
JP (1) JP2003510328A (hu)
KR (1) KR20010087401A (hu)
CN (1) CN1374961A (hu)
AU (1) AU1271201A (hu)
BG (1) BG105650A (hu)
BR (1) BR0007174A (hu)
CA (1) CA2352194A1 (hu)
CZ (1) CZ20012373A3 (hu)
HK (1) HK1048999A1 (hu)
HU (1) HUP0104917A3 (hu)
IL (1) IL143349A0 (hu)
NO (1) NO20012567L (hu)
PL (1) PL347885A1 (hu)
SK (1) SK8842001A3 (hu)
TR (1) TR200101499T1 (hu)
WO (1) WO2001023390A2 (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE546539T1 (de) 2002-07-26 2012-03-15 Basf Plant Science Gmbh Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
ATE541043T1 (de) 2005-03-08 2012-01-15 Basf Plant Science Gmbh Expressionsverstärkende intron-sequenz
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP5922029B2 (ja) 2009-11-27 2016-05-24 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20210125024A (ko) * 2019-02-02 2021-10-15 치아타이 티안큉 파마수티컬 그룹 주식회사 Parp 억제제로서의 인돌로 헵타밀 옥심 유사체
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021318572A1 (en) * 2020-07-31 2023-02-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
HK1048999A1 (zh) 2003-04-25
HUP0104917A3 (en) 2002-12-28
CN1374961A (zh) 2002-10-16
SK8842001A3 (en) 2002-01-07
KR20010087401A (ko) 2001-09-15
IL143349A0 (en) 2002-04-21
NO20012567L (no) 2001-06-25
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
TR200101499T1 (tr) 2002-09-23
WO2001023390A2 (de) 2001-04-05
WO2001023390A3 (de) 2001-12-27
BG105650A (en) 2002-02-28
JP2003510328A (ja) 2003-03-18
NO20012567D0 (no) 2001-05-25
EP1183259A2 (de) 2002-03-06
PL347885A1 (en) 2002-04-22
AU1271201A (en) 2001-04-30
CZ20012373A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
HUP0104917A2 (hu) Azepinoindolszármazékok, előállításuk és alkalmazásuk
HUP0401564A2 (hu) Diaril-cikloalkil-származékok, PPAR aktivátorként történő alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
MXPA02000973A (es) Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
NO20054195D0 (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
HUP0203873A2 (hu) Szubsztituált indolvázú Mannich-bázisok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1527049B8 (en) Fused heterocyclic compounds as peptidase inhibitors
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
HUP0202759A2 (hu) Táptalaj sejtek fehérjementes és szérummentes tenyésztéséhez
HUP0002517A2 (hu) Acil-piperazinilpirimidin-származékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyászati készítmények és gyógyszerként való alkalmazásuk
HUP0300743A2 (hu) Heteroarilszármazékok és alkalmazásuk gyógyszerként
DK1499590T3 (da) Piperidinderivater som kaliumkanalblokkere
HUP0303624A2 (hu) NEP inhibitor hatású N-fenpropil-ciklopentil-csoporttal szubsztituált glutáramid származékok és ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
ATE227719T1 (de) Heteroaryl-zyklische acetale
CO5271716A1 (es) Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
AU2001266575A1 (en) Chemical compounds
HUP0402675A2 (hu) HIV integráz inhibitor hatású hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300127A2 (en) Nematicidal trifluorobutene-derivatives, their preparation, the novel intermediates composition containing the same and use thereof
HUP0302115A2 (hu) Tiazabiciklo[3.2.2]nonán-fenil-izoxazol-származékok, előállításuk és ezeket tartalamzó gyógyszerkészítmények
DK1001937T3 (da) Fremgangsmåde til fremstilling af 2-(3-pyrazolyloxymethylen)nitrobenzener
AU4205197A (en) New thiazole derivatives with phosphodiesterase-inhibiting effect
HK1077596A1 (en) Azo dyestuffs
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
HUP0201910A2 (hu) Új aminobenzofenonszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9901315A2 (hu) Új karbonsavszármazékok, előállításuk és alkalmazásuk
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors